{"id":3153,"date":"2018-02-19T01:07:39","date_gmt":"2018-02-19T06:07:39","guid":{"rendered":"https:\/\/issels.com\/blog\/?p=3153"},"modified":"2018-02-19T07:12:14","modified_gmt":"2018-02-19T12:12:14","slug":"monumental-advances-in-the-treatment-of-bladder-cancer","status":"publish","type":"post","link":"https:\/\/issels.com\/blog\/2018\/02\/19\/monumental-advances-in-the-treatment-of-bladder-cancer\/","title":{"rendered":"Monumental Advances in the Treatment of Bladder Cancer"},"content":{"rendered":"
\"There
There is New Hope for Bladder Cancer Treatment<\/figcaption><\/figure>\n

When it comes to immunotherapy cancer treatment<\/a>, checkpoint inhibitors have been a major game-changer. 2017 alone saw five approvals for checkpoint inhibitors that greatly advanced treatment for bladder cancer<\/a>.<\/p>\n

Bladder Cancer Treatment: The Year in Review<\/strong><\/p>\n

During the Society of Urologic Oncology’s annual meeting in late 2017, speaker Elizabeth Plimack, M.D., recapped the year’s highlights in bladder cancer<\/a> treatments.<\/p>\n

– The good news began in February, with the approval of Opdivo for second-line treatment of bladder cancer as a follow-up to platinum-containing therapy.<\/p>\n

– After approval in 2016 as a second-line treatment, Tecentriq was granted approval as a front-line treatment in April 2017.<\/p>\n

– May 2017 brought about approvals for three more treatments: Imfinzi, Bavencio and Keytruda.<\/p>\n

As Plimack stated during her presentation, these approvals demonstrate that checkpoint inhibitors<\/a> are “here to stay.”<\/p>\n

What Lies Ahead?<\/strong><\/p>\n

One area that needs more research is how to be more accurate in choosing patients who will be most receptive<\/a> to these treatments. Other features that require further studies include duration of response, delayed toxicities and overcoming resistance.<\/p>\n

Plimack’s comments included cautioning against extrapolating the data to patients who are eligible for cisplatin, which is a form of chemotherapy. As Plimack explained, more trials are needed before checkpoint inhibitors are approved to replace cisplatin as first-line treatments.<\/p>\n

Issels\u00ae: Immunotherapy Treatment for Advanced Cancers<\/strong><\/p>\n

We have a successful track record of providing cancer treatment<\/a> that helps patients achieve long-term remission, even in advanced and therapy-resistant cases. Visit our website to hear and read testimonials from patients<\/a> of all ages with various forms of cancer who have been treated at Issels\u00ae.<\/p>\n","protected":false},"excerpt":{"rendered":"

When it comes to immunotherapy cancer treatment, checkpoint inhibitors have been a major game-changer. 2017 alone saw five approvals for checkpoint inhibitors that greatly advanced treatment for bladder cancer. Bladder Cancer Treatment: The Year in Review During the Society of Urologic Oncology’s annual meeting in late 2017, speaker Elizabeth Plimack, M.D., recapped the year’s highlights … Continue reading Monumental Advances in the Treatment of Bladder Cancer<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[202,203,580,205,538,1],"tags":[212,224,531],"class_list":["post-3153","post","type-post","status-publish","format-standard","hentry","category-alternative-cancer-treatment","category-cancer-research","category-cancer-treatment","category-immuno-oncology","category-immunotherapy-for-cancer","category-uncategorized","tag-cancer-research","tag-cancer-treatment","tag-immunotherapy-for-cancer"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/3153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/comments?post=3153"}],"version-history":[{"count":2,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/3153\/revisions"}],"predecessor-version":[{"id":3158,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/3153\/revisions\/3158"}],"wp:attachment":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/media?parent=3153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/categories?post=3153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/tags?post=3153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}